Our study findings suggest significant differences in the prevalence of complications and comorbidities and treatments for Black patients with T2D compared to White and Hispanic patients, with Black patients having higher rates of micro- and macrovascular complications, obesity, and insulin use. This evidence concerns the gene INS and type 2 diabetes mellitus.